Metformin/rosuvastatin - Hanmi Pharmaceutical

Drug Profile

Metformin/rosuvastatin - Hanmi Pharmaceutical

Alternative Names: HCP-1201; Rosuvastatin/metformin

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 31 Jan 2014 Hanmi Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT02026817)
  • 01 Jan 2014 Hanmi Pharmaceutical completes enrolment in a phase I trial in Healthy volunteers in South Korea (NCT02026817)
  • 31 Dec 2013 Hanmi Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT02011633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top